Medications used in the treatment of multiple sclerosis

Physical Medicine and Rehabilitation Clinics of North America

Volumn 10, Issue 2, 1999, Pages 437-446

  Schapiro, R T ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMANTADINE; AZATHIOPRINE; BACLOFEN; BETA INTERFERON; CORTICOTROPIN; DEXAMETHASONE; GAMMA INTERFERON; GLATIRAMER; HUMAN IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; PEMOLINE MAGNESIUM; TIZANIDINE;

CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG CHOICE; HUMAN; MULTIPLE SCLEROSIS; PAIN; PALLIATIVE THERAPY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; SOCIAL ASPECT;

EID: 0033016494     PISSN: 10479651     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1047-9651(18)30204-3     Document Type: Review

References (48)

1. M.L. Aisen M. Holzer M. Rosen Glutethemide treatment of disabling action tremor in patients with multiple sclerosis and traumatic brain injury Arch Neurol 48 1991 513 515
2. S. Baron S.K. Tyring W.R. Fleischmann Jr. The interferons—mechanisms of action and clinical applications JAMA 266 1991 1375 1383
3. R.W. Beck P.A. Cleary M.M. Anderson Jr. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis N Engl J Med 326 1992 581 588
4. R.W. Beck P.A. Cleary J.D. Trobe The effect of corticosteroids for acute optic neuritis and the subsequent development of multiple sclerosis N Engl J Med 329 1993 1764 1769
5. J.G. Blaivas Management of bladder dysfunction in multiple sclerosis Neurology 30 1980 12 18
6. J. Borg-Stein Z.M. Pine R.J. Miller Botulinum toxin for the treatment of spasticity in multiple sclerosis Am J Phys Med Rehabil 72 1993 364 368
7. M.B. Bornstein A. Miller S. Slagle A placebo-controlled, double blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis Neurology 41 1991 533 539
8. + T cells J Exp Med 178 1993 1655 1663
9. J.A. Cohen R.I. Grossman J.K. Udupa Assessment of the efficacy of copolymer 1 in the treatment of multiple sclerosis by quantitative MRI Neurology 45 1995 418
10. R. Cirelli K. Herne S. Tyring Interferons Clinical Immunotherapeutics Supplement 1996 5
11. F.A. Davis D. Stefoski J. Rush Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis Ann Neurol 27 1990 186 192
12. P.C. Dowling W. Bosch S.D. Cook Possible beneficial effect of high-dose intravenous steroid therapy in acute demyelinating disease and transverse myelitis Neurology 30 1980 33 36
13. L. Durelli D. Cocito A. Riccio High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: Clinical immunologic correlations Neurology 36 1986 238 243
14. D.E. Goodkin R.A. Rudick S. Vanderburg Medendrop Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis Ann Neurol 37 1995 30 40
15. S.E. Grassberg Interferons: An overview of their biological and biochemical properties C.M. Pfaeffer Mechanisms of Interferon Actions vol 1 1987 CRC Press Inc New York
16. F.M. Hofman D.R. Hinton K. Johnson Tumor necrosis factor identified in multiple sclerosis brain J Exp Med 170 1989 607 612
17. N.J. Holland A.S. Abramson Bladder and bowel management L.C. Scheinberg Multiple Sclerosis, A Guide for Patients and Their Families 1983 Raven Press New York
18. L. Jacobs J. O’Malley A. Freenan Intrathecal interferon reduces exacerbations of multiple sclerosis Science 214 1981 1026 1028
19. L.D. Jacobs D.L. Cookfair R.A. Rudick Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis Ann Neurol 39 1996 285 294
20. K.P. Johnson B.R. Brooks J.A. Cohen Copolymer 1 reduces relapse rate and improves disability in relap sing-remitting multiple sclerosis: Results of a phase III multicenter, double blind, placebo-controlled trial Neurology 45 1995 1268 1276
21. G.R. Klimpel A.J. Infante J. Patterson Virus-induced interferon a/ß (IFN-a/ß) production by T cells and by Thl and Th2 helper T cell clones: A study of the immunoregulatory actions of IFN-y versus IFN-α/β on functions of different T cell populations Cell Immunol 128 1990 603 618
22. L.B. Krupp L.A. Alvarez N. LaRocca Fatigue in multiple sclerosis Arch Neurol 45 1988 435 437
23. M.J. Kupersmith D. Kaufman D.W. Paty Megadose corticosteroids in multiple sclerosis Neurology 44 1994 1 4
24. Y. Lapierre S. Bouchard C. Tansey Treatment of spasticity with tizanidine in multiple sclerosis Can J Neurol Sci 14 1987 513 517
25. R.Z. Lockhart Criteria for acceptance of viral inhibitor as an interferon and a general description of the biological properties of known interferons N.B. Finter Interferons and Interferon Inducers 1993 Elsevier New York
26. F.D. Lublin S.C. Reingold Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis Neurology 46 1996 907 911
27. G.L. Mancardi F. Sardanelli R.C. Parodi Effect of copolymer-1 on serial gadolinium- enhanced MRI in relapsing remitting multiple sclerosis Neurology 50 1998 1127 1133
28. J. Marshall Spastic paraplegia of middle age—A clinicopathological study Lancet 1 1955 643 646
29. A. Miller Sexual dysfunction in multiple sclerosis in sexual dysfunction C. Singer W.J. Weinger A Neuro-medical Approach 1994 Futura New York
30. T.J. Murray Amantadine therapy for fatigue in multiple sclerosis Can J Neurol Sci 12 1985 251 254
31. R.D. Penn S.M. Savoy D. Corcos Intrathecal baclofen for severe spinal spasticity N Engl J Med 320 1989 1517 1521
32. G.P.A. Rice J. Lesaux P. Vandervoort Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor J Neurol Neurosurg Psychiatry 62 1997 282 284
33. A.S. Rose J.W. Kuzuma J.F. Kurtzke Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs. placebo Final Report 20 1970 1 59
34. R.A. Rudick R.B. Schiffer R.M. Herndon Drug treatment of multiple sclerosis Semin Neurol 7 1987 150 159
35. R.A. Rudick N.A. Simonian J.A. Alam Incidence and significance of neutralizing antibodies to interferon beta-la in multiple sclerosis Neurology 50 1998 1266 1272
36. R.T. Schapiro Bladder in Symptom Management in Multiple Sclerosis ed 3 1998 Demos New York
37. R.T. Schapiro Fatigue in Symptom Management in Multiple Sclerosis 1998 Demos New York
38. R.T. Schapiro Pain in Symptom Management in Multiple Sclerosis ed 3 1998 Demos New York
39. R.T. Schapiro Spasticity in Symptom Management in Multiple Sclerosis ed 3 1998 Demos New York
40. R.T. Schapiro Tremor in Symptom Management in Multiple Sclerosis ed 3 1998 Demos New York
41. R.T. Schapiro S. van den Noort L. Scheinberg The current management of multiple sclerosis Ann N Y Acad Sci 436 1984 425 434
42. P.S. Sorenson B. Wanscher C.V. Jensen Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis Neurology 50 1998 1273 1281
43. I.F.N.B. The Multiple Sclerosis Study Group and the UBC MS/MRI Analysis Group: Interferon beta-lb in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial Neurology 45 1995 1277 1285
44. I.F.N.B. The Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group: Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-lb: Experience during the first three years Neurology 47 1996 889 894
45. B.D. Trapp J. Peterson R.M. Ransohoff Axonal transections in lesions of multiple sclerosis N Engl J Med 338 1998 278 285
46. F.G.A. van der Meché P.I.M. Schmitz Dutch Guillain-Barré Study Group: A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome N Engl J Med 326 1992 1123 1129
47. R.R. Young P.J. Delwaide Drug therapy—Spasticity N Engl J Med 304 1981 28 33
48. P.L. Yudkin G.W. Ellison A. Ghezzi Overview of azathioprine treatment in multiple sclerosis Lancet 338 1991 1051 1055